维斯纳里恢复了早期内毒性病的收缩性和处理能力
K Takeuchi1, P J del Nido, D N Poutias
1Departments of Anesthesiology and Cardiac Surgery and the Anesthesia/Critical Care Medicine Laboratory, Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Circulation
|November 18, 2000
概括
韦斯纳利因恢复处理和收缩力而改善了内毒性心脏功能. 这种药物可以治疗炎症诱导的心肌功能障碍.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生理学 生理学 生理学
背景情况:
- 内毒素 (脂聚糖,LPS) 引发系统性炎症和心脏功能障碍.
- 之前的研究表明,在LPS之前给予vesnarinone和amrinone,可以防止细胞因子的产生和心脏问题.
- 这项研究调查了vesnarinone是否可以改善细胞内处理和在内毒性开始后的收缩性.
研究的目的:
- 为了测试vesnarinone是否改善细胞内Ca2+处理和激活的收缩力在内毒性病.
- 为了评估韦斯纳尼对心肌功能和循环在LPS给药后的影响.
主要方法:
- 成长的子接受LPS或车载,然后90分钟后接受vesnarinone (3mg/kg).
- 心脏在兰登多夫模式下进行了透气;测量包括左心室压力,+/-dp/dt,MVO(2) 和速率-压力产物.
- 细胞内度 (Ca(i)) 和透静去除率 (tauCa) 通过光光谱测定.
主要成果:
- LPS显著降低左心室发育的压力和+/-dp/dt,而vesnarinone完全恢复了这种情况.
- 韦斯纳尼在LPS心脏中纠正了较慢的透析去除 (增加tauCa),但仅部分改善了细胞过载.
- 在用LPS治疗的子中,Vesnarinone改善了降低机械效率和肌纤维对Ca的敏感性.
结论:
- 急性内毒症通过收缩蛋白质不敏感,氧气浪费和异常循环诱导心肌功能障碍.
- 作为救援疗法使用的维斯纳利能使LPS诱导的心肌功能障碍正常化,并部分恢复了循环.
- 像维斯纳尼这样的药物显示出治疗炎症诱导的心肌功能障碍的潜力,尽管机制需要进一步研究.
相关概念视频
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
2.4K
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
2.4K
01:26Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K